All News
RheumNow Podcast – What You Do For & What You Do To the Patient (4.8.2022)
Dr. Jack Cush reviews the news and journal articles from the past week and discusses the use of fibroscan in RA, steroid hip injections in OA and famous quotes from a famous cardiologist.
Read Article
Short-Term (not Long-Term) Benefits to Intraarticular Hip Steroid Injection
A single ultrasound guided intra-articular hip corticosteroid injection can be quite effective in patients with hip osteoarthritis (OA).
Read Article
TNR Recap: What Patients Say about PsA
Watch this outstanding and informative Tuesday Nite Rheumatology, held on April 5th, 2022 which featured a Patient Perspectives panel discussion, hosted by Dr. Jack Cush.
PsA Panelists included:
- Tena Brown
- Christine Lindsay
- Ashley Krivohlavek
Read Article
I signed up for a great LUPUS Symposia on Saturday May 7th. Its all about the future of #SLE! You should register. Check out the all-start faculty! Drs. Chakravarty, Clowse, Costenbader, Furie, James, Kalunian, Kim, Merrill, Mohan, Pascual, Petri https://t.co/eZIJoEEzo9 https://t.co/09Da4kEUUF
Links:
Dr. John Cush RheumNow ( View Tweet)
CorEvitas Registry study of Axial #PsA pts showed 6 mos of bDMARD/tsDMARD resulted in modest, nonsignificant improvement axial outcomes,(irrespective HLA-B27 status), including ASDAS40, BASDAI50, & spinal pain. 31% of pts were B27+ https://t.co/9m9H7PwIIF #PsAlways https://t.co/dYk5GfIdez
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA has granted a Priority Review for tocilizumab (Actemra) intravenous for the treatment of hospitalised COVID-19 adults receiving systemic corticosteroids and require supplemental O2, mechanical ventilation, or ECMO. https://t.co/b4GSuvsElp https://t.co/oEGskAJVyd
Links:
Dr. John Cush RheumNow ( View Tweet)
COMPLETE-PsA Trial studied MTX vs MTX + leflunomide in 78 active untreated PsA pts. MTX+LEF was superior to MTX alone at wk 16 (PASDAS 3·1 vs 3·7; p=0·025). Combo group had more N/V (44% v 28%), ^ALT (31% vs 18%). https://t.co/Hc4rNrlQzP https://t.co/UPosZIc4C0
Links:
Dr. John Cush RheumNow ( View Tweet)
Deucravacitinib, TYK2 inhib, studied in phase II trial 203 active PsA pts randomised to PBO, or DEUC 6 mg or 12 mg qd. At wk 16 ACR-20 responses were significantly higher with DEUC 6mg (53%, p=0.0134) and 12 mg (63%, p=0.0004) vs PBO. https://t.co/0nvutsXHsI https://t.co/jh43zCbdZx
Links:
Dr. John Cush RheumNow ( View Tweet)
Differences between Palpated & Ultrasound Joint exams in 155 #PSA patients. 5616 joints - found 18.5% tender, 9.8% swollen, 20.4% w/ US GS ≥ 2 and 5.2% had US PD ≥ 1. Joints that were both tender and swollen more likely to have GS ≥ (44%) https://t.co/nWI7jLdkWp https://t.co/iRNsqWYScM
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheum Comanagement of Psoriasis
https://t.co/vXF4t2IIoW
QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022 https://t.co/fDVx49XtYP
Links:
Dr. John Cush RheumNow ( View Tweet)
“Do as much as possible for the patient, & as little as possible to the patient.” (B Lown). JAMA review of Antithrombotics in COVID-19 says all hospitalized COVID pts with COVID-19 should recv anticoagulation with heparin; no proven value to anti-Plts Rx https://t.co/ZfaH4FiRy1 https://t.co/DW8BGKjfnX
Links:
Dr. John Cush RheumNow ( View Tweet)
Dactylitis Indicates a Severe PsA Phenotype
https://t.co/bUg15czr1Q https://t.co/bnawRJ20jj
Links:
Dr. John Cush RheumNow ( View Tweet)
Among 1033 #PSA pts - 37% were obese. Obese PsA pts had higher PsAQoL, HADS-Anxiety, HADS-Depression, DAPSA, DAS28-CRP, BASDAI, BASFI, HAQ &FACIT scores (p<0.05). BMI affects QOL, depression, disease activity, fatigue https://t.co/6PD8G6xFnk https://t.co/Wlgp0gJGbK
Links:
Dr. John Cush RheumNow ( View Tweet)
This week's Daily Download includes 9 slides covering Moll & Wright classification; epidemiology & prevalence; factors; skin & joint images, and more.
https://t.co/Pr7vODmmnr https://t.co/TEzUy5r4rZ
Links:
Dr. John Cush RheumNow ( View Tweet)
Australian study from 2 #PSA clinics PsA clinics compared RAPID3 score to MDA, very low disease activity (VLDA) & DAPSA. 93 pts showed RAPID3 correlated w/ ROC AUC for VLDA (0.94) and DAPSA (0.96) https://t.co/x9G8wTpeS6 #PsAlways https://t.co/WuseKMoiJj
Links:
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - PsA Lessons from the Clinic
Does the Moll & Wright Classification of PsA hold up?
QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022
https://t.co/zskcsZ4kkW https://t.co/QZOb09wGyp
Links:
Dr. John Cush RheumNow ( View Tweet)
Czech registry compared drug survival csDMARDs vs TNFi monotherapy. Drug retention higher w/ combo (47 vs 23 mos; p < 0.001) than TNFi monotherapy. 5 yr survival was better 45% vs 26%; Combo w/ MTX > other csDMARDs (p = 0.003). https://t.co/pjbXwEQ53K https://t.co/nZj64Wk3Pt
Links:
Dr. John Cush RheumNow ( View Tweet)
520 RA pts were screened with FibroScan (liver fibrosis)- F3 or F4 liver fibrosis seen 13.3% of controls vs 12.7% arthritis pts. MTX was not significantly correlated w/ higher FS scores. Liver stiffness was correlated w/ BMI, waist, male , age. https://t.co/iKvsITCs33 https://t.co/Dqos1MT431
Links:
Dr. John Cush RheumNow ( View Tweet)
Steroids associated with adverse events during pregnancy @UmaMahadevanIBD @MayoClinicGIHep https://t.co/VR5CZUH1S7
Edward Loftus EdwardLoftus2 ( View Tweet)
Avacopan efficacy in renal failure in AAV. Appears to have benefit in renal disease that is more marked the more severe the disease is #Vasculitis22 https://t.co/3zsxjTLj62
Richard Conway RichardPAConway ( View Tweet)